172 related articles for article (PubMed ID: 20795948)
1. 14-3-3 proteins are promising LRRK2 interactors.
Rudenko IN; Cookson MR
Biochem J; 2010 Sep; 430(3):e5-6. PubMed ID: 20795948
[TBL] [Abstract][Full Text] [Related]
2. 14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization.
Nichols RJ; Dzamko N; Morrice NA; Campbell DG; Deak M; Ordureau A; Macartney T; Tong Y; Shen J; Prescott AR; Alessi DR
Biochem J; 2010 Sep; 430(3):393-404. PubMed ID: 20642453
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser(910)/Ser(935), disruption of 14-3-3 binding and altered cytoplasmic localization.
Dzamko N; Deak M; Hentati F; Reith AD; Prescott AR; Alessi DR; Nichols RJ
Biochem J; 2010 Sep; 430(3):405-13. PubMed ID: 20659021
[TBL] [Abstract][Full Text] [Related]
4. Measurement of LRRK2 and Ser910/935 phosphorylated LRRK2 in peripheral blood mononuclear cells from idiopathic Parkinson's disease patients.
Dzamko N; Chua G; Ranola M; Rowe DB; Halliday GM
J Parkinsons Dis; 2013; 3(2):145-52. PubMed ID: 23938344
[TBL] [Abstract][Full Text] [Related]
5. Phosphorylation of LRRK2 serines 955 and 973 is disrupted by Parkinson's disease mutations and LRRK2 pharmacological inhibition.
Doggett EA; Zhao J; Mork CN; Hu D; Nichols RJ
J Neurochem; 2012 Jan; 120(1):37-45. PubMed ID: 22004453
[TBL] [Abstract][Full Text] [Related]
6. The IkappaB kinase family phosphorylates the Parkinson's disease kinase LRRK2 at Ser935 and Ser910 during Toll-like receptor signaling.
Dzamko N; Inesta-Vaquera F; Zhang J; Xie C; Cai H; Arthur S; Tan L; Choi H; Gray N; Cohen P; Pedrioli P; Clark K; Alessi DR
PLoS One; 2012; 7(6):e39132. PubMed ID: 22723946
[TBL] [Abstract][Full Text] [Related]
7. Conformational heterogeneity of the Roc domains in C. tepidum Roc-COR and implications for human LRRK2 Parkinson mutations.
Rudi K; Ho FY; Gilsbach BK; Pots H; Wittinghofer A; Kortholt A; Klare JP
Biosci Rep; 2015 Aug; 35(5):. PubMed ID: 26310572
[TBL] [Abstract][Full Text] [Related]
8. LRRK2 and ubiquitination: implications for kinase inhibitor therapy.
Melrose HL
Biochem J; 2015 Sep; 470(3):e21-4. PubMed ID: 26341487
[TBL] [Abstract][Full Text] [Related]
9. Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C/G mutants.
Li X; Tan YC; Poulose S; Olanow CW; Huang XY; Yue Z
J Neurochem; 2007 Oct; 103(1):238-47. PubMed ID: 17623048
[TBL] [Abstract][Full Text] [Related]
10. The Roc domain of LRRK2 as a hub for protein-protein interactions: a focus on PAK6 and its impact on RAB phosphorylation.
Cogo S; Ho FY; Tosoni E; Tomkins JE; Tessari I; Iannotta L; Montine TJ; Manzoni C; Lewis PA; Bubacco L; Chartier Harlin MC; Taymans JM; Kortholt A; Nichols J; Cendron L; Civiero L; Greggio E
Brain Res; 2022 Mar; 1778():147781. PubMed ID: 35016853
[TBL] [Abstract][Full Text] [Related]
11. Expression, purification and preliminary biochemical and structural characterization of the leucine rich repeat namesake domain of leucine rich repeat kinase 2.
Vancraenenbroeck R; Lobbestael E; Weeks SD; Strelkov SV; Baekelandt V; Taymans JM; De Maeyer M
Biochim Biophys Acta; 2012 Mar; 1824(3):450-60. PubMed ID: 22251894
[TBL] [Abstract][Full Text] [Related]
12. The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity.
Gloeckner CJ; Kinkl N; Schumacher A; Braun RJ; O'Neill E; Meitinger T; Kolch W; Prokisch H; Ueffing M
Hum Mol Genet; 2006 Jan; 15(2):223-32. PubMed ID: 16321986
[TBL] [Abstract][Full Text] [Related]
13. Phosphorylation-dependent 14-3-3 binding to LRRK2 is impaired by common mutations of familial Parkinson's disease.
Li X; Wang QJ; Pan N; Lee S; Zhao Y; Chait BT; Yue Z
PLoS One; 2011 Mar; 6(3):e17153. PubMed ID: 21390248
[TBL] [Abstract][Full Text] [Related]
14. The Roc-COR tandem domain of leucine-rich repeat kinase 2 forms dimers and exhibits conventional Ras-like GTPase properties.
Mills RD; Liang LY; Lio DS; Mok YF; Mulhern TD; Cao G; Griffin M; Kenche VB; Culvenor JG; Cheng HC
J Neurochem; 2018 Nov; 147(3):409-428. PubMed ID: 30091236
[TBL] [Abstract][Full Text] [Related]
15. Analysis of LRRK2 accessory repeat domains: prediction of repeat length, number and sites of Parkinson's disease mutations.
Mills RD; Mulhern TD; Cheng HC; Culvenor JG
Biochem Soc Trans; 2012 Oct; 40(5):1086-9. PubMed ID: 22988870
[TBL] [Abstract][Full Text] [Related]
16. The GTPase function of LRRK2.
Taymans JM
Biochem Soc Trans; 2012 Oct; 40(5):1063-9. PubMed ID: 22988866
[TBL] [Abstract][Full Text] [Related]
17. Prediction of the repeat domain structures and impact of parkinsonism-associated variations on structure and function of all functional domains of leucine-rich repeat kinase 2 (LRRK2).
Mills RD; Mulhern TD; Liu F; Culvenor JG; Cheng HC
Hum Mutat; 2014 Apr; 35(4):395-412. PubMed ID: 24470158
[TBL] [Abstract][Full Text] [Related]
18. Homo- and heterodimerization of ROCO kinases: LRRK2 kinase inhibition by the LRRK2 ROCO fragment.
Klein CL; Rovelli G; Springer W; Schall C; Gasser T; Kahle PJ
J Neurochem; 2009 Nov; 111(3):703-15. PubMed ID: 19712061
[TBL] [Abstract][Full Text] [Related]
19. Parkinson-related LRRK2 mutation R1441C/G/H impairs PKA phosphorylation of LRRK2 and disrupts its interaction with 14-3-3.
Muda K; Bertinetti D; Gesellchen F; Hermann JS; von Zweydorf F; Geerlof A; Jacob A; Ueffing M; Gloeckner CJ; Herberg FW
Proc Natl Acad Sci U S A; 2014 Jan; 111(1):E34-43. PubMed ID: 24351927
[TBL] [Abstract][Full Text] [Related]
20. The Parkinson disease gene LRRK2: evolutionary and structural insights.
Marín I
Mol Biol Evol; 2006 Dec; 23(12):2423-33. PubMed ID: 16966681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
